Table I.
Characteristics of patients with post-chemotherapy CHIP, and specific mutations identified.
| Age (years) | Sex | Race | Cancer | Chemo-therapy | Months from treatment | CHIP-associated mutations |
|---|---|---|---|---|---|---|
| 49 | F | W | Breast | ACT | 20 | DNMT3A |
| 50 | F | W | Breast | ACT | 7 | DNMT3A (x2) |
| 54 | F | B | Lymphoma | ABVD | 23 | DNMT3A |
| 59 | F | W | Breast | ACT | 9 | GNAS |
| 61 | F | W | Lymphoma | ABVD | 91 | DNMT3A |
| 62 | F | W | Breast | ACT | 18 | ASXL1, DNMT3A, TET2 |
| 64 | M | W | Lymphoma | RCHOP | 57 | DNMT3A, TP53 |
| 65 | F | W | Lymphoma | RCHOP | 44 | TET2 |
| 67 | M | W | Lymphoma | RCHOP | 119 | KIT, SRSF2 |
| 67 | F | W | Lymphoma | RCHOP | 8 | TET2 |
| 69 | F | W | Breast | ACT | 10 | ASXL1, DNMT3A |
| 69 | M | W | Lymphoma | RCHOP | 100 | ASXL1, BCORL1, SRSF2, ZRSR2 |
| 71 | F | W | Breast | AC | 53 | DNMT3A (x2) |
| 71 | F | W | Breast | ACT | 59 | DNMT3A |
| 75 | F | W | Lymphoma | CHOP | 67 | DNMT3A, TET2 |
ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; AC: doxorubicin and cyclophosphamide; ACT: doxorubicin, cyclophosphamide and paclitaxel; B: black; CHIP: clonal haematopoiesis of indeterminate potential; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisone; F: female; M: male; RCHOP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; W: white non-Hispanic.